Cytek Biosciences, Inc. (CTKB) Income Statement
CTKB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCTKB revenue and net income
Where CTKB's revenue goes
2025Each bar shows an amount and its share of revenue. CTKB kept −33.0% of revenue as net income.
CTKB profit margins
CTKB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.5% | +7.1% | +16.8% | — |
| Gross profit | −6.0% | +1.1% | +15.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | −175.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CTKB quarterly EPS vs estimates
Cytek Biosciences beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.05).
CTKB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M | $92.8M | $57.9M |
| Cost of revenue | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M | $41.1M | $29.2M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M | $51.7M | $28.7M |
| Research & development | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M | $13.7M | $8.9M |
| Sales, general & admin | $108.4M | $92.2M | $93.1M | $67.9M | $45.5M | $24.4M | $17.0M |
| Total operating expenses | $144.8M | $131.6M | $137.3M | $102.8M | $70.0M | $38.1M | $45.9M |
| Operating income | −$40.4M | −$20.5M | −$27.8M | −$1.8M | $9.2M | $13.7M | −$17.3M |
| Interest income | $2.2M | $10.4M | $7.6M | $4.6M | $49,000 | $110,000 | $711,000 |
| Interest expense | $474,000 | $5.2M | $2.1M | $2.6M | $1.7M | $333,000 | $1,000 |
| Income before taxes | −$29.8M | −$5.7M | −$15.7M | $1.3M | $5.9M | $14.4M | −$16.3M |
| Income taxes | $36.7M | $320,000 | −$3.6M | −$1.2M | $2.9M | −$5.0M | $533,000 |
| Net income | −$66.5M | −$6.0M | −$12.1M | $2.6M | $3.0M | $19.4M | −$16.8M |
| EBITDA | −$17.4M | $4.8M | −$4.4M | $9.5M | $8.9M | $15.4M | −$16.0M |
| EPS (diluted) | −$0.12 | $0.16 | −$0.05 | $0.11 | $0.11 | $0.16 | −$0.03 |
| Gross margin | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% | 49.5% |
| Operating margin | −20.0% | −10.2% | −14.4% | −1.1% | 7.2% | 14.7% | −29.8% |
| Net margin | −33.0% | −3.0% | −6.3% | 1.6% | 2.3% | 20.9% | −29.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $44.1M | $62.1M | $52.3M | $45.6M | $41.5M | $57.5M | $51.5M | $46.6M | $44.9M | $58.2M | $48.0M |
| Cost of revenue | $19.8M | $22.9M | $29.3M | $24.7M | $21.7M | $21.3M | $23.8M | $22.5M | $21.2M | $21.8M | $25.2M | $20.8M |
| Gross profit | $28.3M | $21.3M | $32.9M | $27.6M | $23.9M | $20.2M | $33.7M | $29.0M | $25.4M | $23.0M | $33.0M | $27.2M |
| Research & development | $9.7M | $9.6M | $9.0M | $9.0M | $8.8M | $9.7M | $9.7M | $9.9M | $10.0M | $9.8M | $10.9M | $11.2M |
| Sales, general & admin | $30.0M | $30.1M | $29.5M | $27.8M | $25.7M | $25.4M | $20.9M | $23.4M | $24.0M | $24.0M | $22.3M | $22.4M |
| Total operating expenses | $39.7M | $39.7M | $38.5M | $36.7M | $34.5M | $35.1M | $30.7M | $33.3M | $34.0M | $33.7M | $33.2M | $33.6M |
| Operating income | −$11.4M | −$18.5M | −$5.6M | −$9.2M | −$10.6M | −$15.0M | $3.0M | −$4.2M | −$8.5M | −$10.7M | −$137,000 | −$6.4M |
| Interest income | $819,000 | $787,000 | $580,000 | $573,000 | $555,000 | $508,000 | $6.2M | $1.4M | $1.4M | $1.4M | $1.4M | $1.6M |
| Interest expense | $281,000 | $262,000 | $725,000 | $494,000 | $414,000 | $291,000 | $694,000 | $119,000 | $134,000 | $441,000 | $394,000 | $595,000 |
| Income before taxes | −$11.6M | −$17.4M | −$4.0M | −$7.8M | −$6.8M | −$11.3M | $10.3M | $157,000 | −$7.2M | −$9.0M | $4.1M | −$4.2M |
| Income taxes | $515,000 | $1.5M | $40.0M | −$2.3M | −$1.2M | $136,000 | $680,000 | −$784,000 | $3.2M | −$2.8M | −$1.4M | $2.3M |
| Net income | −$12.2M | −$18.9M | −$44.1M | −$5.5M | −$5.6M | −$11.4M | $9.6M | $941,000 | −$10.4M | −$6.2M | $5.5M | −$6.5M |
| EBITDA | −$8.4M | −$14.3M | −$263,000 | −$4.2M | −$3.4M | −$8.1M | −$2.5M | $3.1M | −$4.6M | −$6.1M | $6.9M | −$1.0M |
| EPS (diluted) | −$0.09 | −$0.10 | −$0.04 | −$0.04 | −$0.01 | −$0.03 | $0.12 | $0.06 | −$0.01 | −$0.01 | $0.04 | −$0.01 |
| Gross margin | 58.9% | 48.2% | 52.9% | 52.7% | 52.3% | 48.6% | 58.5% | 56.3% | 54.6% | 51.3% | 56.8% | 56.6% |
| Operating margin | −23.7% | −41.8% | −9.0% | −17.6% | −23.3% | −36.1% | 5.2% | −8.2% | −18.3% | −23.9% | −0.2% | −13.4% |
| Net margin | −25.3% | −42.7% | −70.9% | −10.5% | −12.2% | −27.5% | 16.8% | 1.8% | −22.4% | −13.8% | 9.4% | −13.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CTKB's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CTKB financial results
In fiscal year 2025 (ended December 31, 2025), Cytek Biosciences reported revenue of $201.5 million, up 0.5% from the year before. It had a net loss of $66.5 million, a net profit margin of −33.0%. Diluted earnings per share came to −$0.12. Over five years revenue grew at an average rate of 16.8% a year.
See the CTKB stock overview for the latest quote and news, or the CTKB chart for price history and technical indicators.
CTKB income statement FAQ
What is Cytek Biosciences's annual revenue?
Cytek Biosciences reported total revenue of $201.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.5% from $200.5 million the previous year.
Is Cytek Biosciences profitable?
No. Cytek Biosciences reported a net loss of $66.5 million in fiscal 2025, a net profit margin of −33.0%; its operating margin was −20.0%.
What is Cytek Biosciences's gross margin?
Cytek Biosciences's gross margin was 51.8% in fiscal 2025: for every $100 of revenue, Cytek Biosciences kept $52 after the direct cost of its products and services.
How much does Cytek Biosciences spend on research and development?
Cytek Biosciences spent $36.5 million on research and development in fiscal 2025, 18.1% of revenue.
How fast is Cytek Biosciences growing?
Revenue grew 16.8% a year on average over the last five fiscal years, from $92.8 million to $201.5 million.
What are Cytek Biosciences's earnings per share?
Cytek Biosciences earned $-0.12 per diluted share in fiscal 2025, compared with $0.16 a year earlier.
When will Cytek Biosciences report its next earnings?
Cytek Biosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Cytek Biosciences's fiscal year end?
Cytek Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.